← Scroll for more →
AbbVie Inc. (ABBV)
Pharmaceutical Preparations
Latest Price
$290.79
TTM P/E
82.14
Normalized P/E
73.55
TTM Div Yield
2.35%
Fwd Div Yield
2.35%
Book Value
0.80
P/B Ratio
362.04
Valuation metrics
adjust assumptions →Norm. op. income: $13.0B (median of 7yr)
Tax rate: 12%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$29.62
90% downside
Base FCF: $22.0B (median of recent 5yr)
Growth: 5%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$178.59
39% downside
EPS: $2.36
Target P/E: 74×
Formula: EPS × P/E
P/E Fair Value
$174.64
40% downside
Institutional Ownership
76.5% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 149.49M | $37.62B | 8.46% | -1.26M | 2026-06-30 |
| Vanguard Capital Management LLC | 115.40M | $29.04B | 6.53% | +515.8K | 2026-06-30 |
| State Street Corp | 82.60M | $20.78B | 4.67% | +1.38M | 2026-06-30 |
| Vanguard Portfolio Management LLC | 48.48M | $12.20B | 2.74% | -1.05M | 2026-06-30 |
| JPMorgan Chase & Co | 47.86M | $12.17B | 2.71% | -4.53M | 2026-06-30 |
| Geode Capital Management, LLC | 47.00M | $11.80B | 2.66% | +260.9K | 2026-06-30 |
| Morgan Stanley | 38.90M | $9.79B | 2.20% | +884.2K | 2026-06-30 |
| Capital Research Global Investors | 30.10M | $7.57B | 1.70% | -1.15M | 2026-06-30 |
| Norges Bank | 25.55M | $6.43B | 1.45% | -114.2K | 2026-06-30 |
| Bank of America Corp | 21.24M | $5.34B | 1.20% | -2.70M | 2026-06-30 |